Mid Cap Pharma Sector Stock Announces Record Date For Rs1.50/Share Dividend

Small Cap pharmaceuticals sector company, Aarti Industries Ltd on July 12, 2023 fixed July 28, 2023 as the record date for final dividend for the financial year ended 2022-23. Aarti Industries shares declined 32% in last 1-year. Currently, Aarti Industries shares are trading 1.76% away from 52-week low price of Rs 447.60 per share. Check details below:

Aarti Industries Fixes Record Date For Final Dividend: As per the BSE filing of the company dated July 12, 2023, "In continuation to our intimation dated May 8, 2023, wherein it was informed that the Board of Directors of the Company have inter-alia recommended Final Dividend @30% i.e. Rs.1.50/- per Equity Share of Rs.5/- each for the Financial Year 2022-23, subject to the approval of the Members at the ensuing 40th Annual General Meeting (AGM) scheduled to be held on Friday, August 4, 2023."

Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Friday, July 28, 2023 as the Record Date for the purpose of determining the Members eligible to receive the Final Dividend for the Financial Year ended 2022-23."

Aarti Industries Stock Performance & Return: Last trading price of Aarti Industries share is Rs 455.60 and it is very near to its 52-week low price of Rs 447.60 per share. Aarti Industries stock hit its new 52-week low value on July 11, July 10, July 7, and July 6, 2023. Aarti Industries shares declined 42% in last 2-years, gave 5% return in last 3-years, and 60% return in last 5-years.

Aarti Industries Financial Outlook: The company for the quarter ended March 31, 2023 declared its consolidated total income at Rs 1656.00 crore, down marginally by .72% from preciding quarter total income of Rs 1667.96 crore. It announced its net profit after tax in latest quarter at Rs 149.00 crore.

Disclaimer: The stock just highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for ay losses. Please consult a professional advisor.